Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
CarcinomaRenal Cell1 moreThe primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus], administered intravenously [IV] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa [IFN alfa] subcutaneously [SC] three times per week [TIW], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter1 moreRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective for transitional cell cancer of the urothelium. PURPOSE: Randomized phase II/III trial to compare different combination chemotherapy regimens in treating patients who have transitional cell cancer of the urothelium.
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
Kidney CancerRATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.
Oxaliplatin in Treating Patients With Metastatic Bladder Cancer
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have metastatic bladder cancer.
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable...
Kidney CancerRATIONALE: Interferon alfa-2b may interfere with the growth of the cancer cells. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if interferon alfa-2b is more effective with or without thalidomide in treating kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa-2b with or without thalidomide in treating patients who have previously untreated metastatic or unresectable kidney cancer.
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter1 moreRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have metastatic cancer of the urinary tract.
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic...
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder Cancer4 morePhase II trial to study the effectiveness of combining trastuzumab with combination chemotherapy in treating patients who have locally recurrent or metastatic urinary tract cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased...
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter1 moreRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced cancer of the urothelium with decreased kidney function.
Erlotinib in Treating Patients With Advanced Kidney Cancer
Kidney CancerRATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have advanced kidney cancer.
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or...
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter1 moreRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells and decrease the need for surgery. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by observation or surgery to remove the bladder (cystectomy) in treating patients who have stage II or stage III cancer of the urothelium.